Investor Day November 2025 Agenda Slide | 1 | Business Overview & Key Investment Highlights | | --- | --- | | 2 | How Organ Transplantation Works | | 3 | Logistics Services | | 4 | Organ Recovery Clinical Services | | 5 | Organ Placement Services | | 6 | Cardiac Care Clinical Services | | 7 | Regulatory Update | | 8 | Technology | | 9 | Unit Economics & Contract Structure | | 10 | Financial Performance and Outlook | | 11 | Q&A 2 | FORWARD LOOKING STATEMENTS This presentation contains "forward-looking statem ...

Financial Data and Key Metrics Changes - Revenue rose 36.7% year-over-year to $49.3 million in Q3 2025, with a 29% increase excluding Keystone [11][12] - Medical segment-adjusted EBITDA margin increased to over 15% in Q3 2025, compared to 10.8% in the prior year period [6][12] - Free cash flow from continuing operations was approximately $2 million in the quarter, with expectations for consistent free cash flow generation moving forward [14][17] Business Line Data and Key Metrics Changes - Organ placement services revenue more than doubled year-over-year, indicating strong growth in this segment [11] - Keystone contributed $2.8 million in revenue for half a month, with a full month revenue increase of over 40% year-over-year [12] - The medical segment-adjusted EBITDA margins improved sequentially to 15.1% in Q3 2025, driven by better performance in the fleet [12] Market Data and Key Metrics Changes - Industry-wide NRP adoption rates continued to increase during Q3, with transplants of organs that have undergone NRP approximately doubling versus the prior year [9] - Despite a seasonal decline in industry transplant volumes of approximately 6%, the company achieved a 3% sequential revenue increase [11] Company Strategy and Development Direction - The company has rebranded as Strata Critical Medical and shifted focus to healthcare, aiming for long-term growth and value creation [5] - The integration of Keystone and the launch of a new clinical services division positions the company as an end-to-end organ recovery platform [8] - The strategy includes co-locating resources to reduce costs and improve service delivery efficiency [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand seen in Q3, leading to an increase in 2025 revenue guidance to $185 million-$195 million [17] - The company anticipates continued growth driven by new technology and evolving regulations in the transplant industry [23] - Management noted that the seasonal decline in transplant volumes is expected and has been historically observed, but the company is growing through this seasonality [40] Other Important Information - The company ended the quarter with no debt and approximately $76 million in cash and short-term investments [16] - A legal provision was booked during the quarter for ongoing litigation related to the go-public transaction [17] Q&A Session Summary Question: Can you provide a disaggregation of where the growth came from in terms of revenue during Q3? - Management indicated that growth was a mix of new customer acquisition and strength within existing customers, with a broadened suite of services contributing to revenue growth [21][22] Question: Do you see the growth coming from similar directions in the future? - Management expects continued customer acquisition and market share consolidation, supported by a favorable industry growth trajectory [23] Question: What should be expected in terms of fleet margin and maintenance impact? - Management noted that scheduled maintenance events have decreased and margins are expected to improve sequentially [24] Question: How many individual customers are being served now post-Keystone acquisition? - Management stated that there are almost 250 different customers across the cardiac care and transplant businesses, providing geographic diversity [30] Question: Is there any customer that constitutes 5% or more of revenues? - Management did not disclose specific customer revenue contributions but emphasized a diversified customer base [31] Question: Will there be a breakdown of logistics versus perfusionist services? - Management indicated that a pro forma 2025 business mix will be provided, reflecting the expected shift towards fast-growing subsectors of the transplant industry [35][36]

Financial Data and Key Metrics Changes - Revenue increased by 36.7% year-over-year to $49.3 million in Q3 2025, with a 29% increase excluding Keystone [11][12] - Medical segment-adjusted EBITDA margin rose to 15.1% in Q3 2025 from 12.5% in the first half of the year [12][13] - Free cash flow from continuing operations was approximately $2 million for the quarter [13] Business Line Data and Key Metrics Changes - Organ placement services revenue more than doubled year-over-year, indicating strong growth in this area [11] - Air logistics contributed significantly to organic revenue growth, with new and existing customers driving strong results [11][12] - Keystone's revenue increased over 40% year-over-year for the full month of September, despite only contributing $2.8 million for half of Q3 [12] Market Data and Key Metrics Changes - Industry-wide NRP adoption rates continued to increase, with transplants of organs undergoing NRP approximately doubling compared to the prior year [9][10] - Despite a seasonal decline in industry transplant volumes of approximately 6%, the company achieved a 3% sequential revenue increase [11] Company Strategy and Development Direction - The company has rebranded as Strata Critical Medical and shifted focus to healthcare, aiming for long-term growth and value creation [5] - The integration of Keystone Perfusion is expected to enhance operational efficiencies and cost savings for the transplant community [8][9] - The company plans to leverage local resources to reduce transportation costs and improve service delivery [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand seen in Q3, leading to an increase in 2025 revenue guidance to a range of $185 million-$195 million [16] - The company anticipates continued growth driven by new customer acquisitions and market share consolidation in a fragmented marketplace [22] - Management acknowledged the impact of seasonal factors on transplant volumes but emphasized the company's ability to grow through these challenges [39] Other Important Information - The company ended the quarter with no debt and approximately $76 million in cash and short-term investments [15] - The Joby transaction closed during the quarter, with cash proceeds of approximately $70 million from monetizing shares [15] Q&A Session Summary Question: Can you provide a disaggregation of where the growth came from in terms of revenue during Q3? - Management indicated that growth was driven by a mix of new customer acquisition and strength within existing customers, with new services contributing to the results [20][21] Question: Do you see the growth coming from similar directions in the future? - Management expects continued customer additions and market share consolidation, supported by favorable industry growth dynamics [22] Question: What should we expect in terms of fleet margin and maintenance impact for the remainder of the year? - Management noted that scheduled maintenance events have decreased and margins are expected to improve sequentially [23] Question: How many individual customers are being served now with the Keystone acquisition? - The company serves almost 250 different customers across cardiac care and transplant businesses, providing geographic diversity [29] Question: Is there any customer that constitutes 5% or more of revenues? - Management stated that the business is diversified, and they do not break out customer contributions by business line [30] Question: Are you evening out the revenue sides between air and ground logistics? - Air remains the larger part of the business, but the Keystone acquisition provides opportunities for ground logistics growth [32] Question: Will you break out logistics versus perfusionist side in the future? - Management indicated that a pro forma business mix will be provided in the investor deck, reflecting the expected future mix [33]

Financial Performance & Acquisitions - Strata's Q3 2025 revenue reached $493 million, a 37% year-over-year increase, with 29% organic growth excluding the Keystone acquisition[5] - The acquisition of Keystone Perfusion contributed approximately $28 million to Strata's Q3 2025 revenue[6] - Adjusted EBITDA for Q3 2025 was $42 million, representing an 85% margin[5] - Strata sold its passenger business to Joby Aviation for $125 million[14] - Strata acquired Keystone Perfusion for $124 million upfront, with potential earn-outs of $23 million based on gross profit targets[15] Market Position & Growth Strategy - Strata estimates its market share to be approximately 30% in air logistics and 15% in ground logistics for organ transport[11] - The company is focused on expanding its transplant clinical services, particularly Normothermic Regional Perfusion (NRP), driven by a 20%+ CAGR in Donation after Circulatory Death (DCD) donors[43] - Strata aims to increase aircraft utilization and improve operating costs by expanding into other time-critical logistics verticals[55] Organ Transplant Trends - The distance of heart, liver, and lung transplants has increased by 64% from 2018 to 2024 due to regulatory changes and new technologies[39] - Normothermic Regional Perfusion (NRP) penetration of DCD donors has increased to approximately 40% by Q3 2025[43] - U S heart, liver, and lung transplants have grown at a CAGR of 38% from 2010-2024[27]